Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Standards for global cardiovascular risk management arteriosclerosis.
Mostaza JM, Pintó X, Armario P, Masana L, Ascaso JF, Valdivielso P; en nombre de la Sociedad Española de Arteriosclerosis; Miembros de la Sociedad Española de Arteriosclerosis. Mostaza JM, et al. Among authors: pinto x. Clin Investig Arterioscler. 2019 Jul;31 Suppl 1:1-43. doi: 10.1016/j.arteri.2019.03.004. Epub 2019 Apr 11. Clin Investig Arterioscler. 2019. PMID: 30981542 Free article. English, Spanish.
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J; HDL Forum. Ascaso JF, et al. Among authors: pinto x. Am J Cardiovasc Drugs. 2004;4(5):299-314. doi: 10.2165/00129784-200404050-00003. Am J Cardiovasc Drugs. 2004. PMID: 15449972 Review.
Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment.
Lahoz C, Peña R, Mostaza JM, Laguna F, García-Iglesias MF, Taboada M, Pintó X. Lahoz C, et al. Among authors: pinto x. Metabolism. 2005 Jun;54(6):741-7. doi: 10.1016/j.metabol.2004.12.020. Metabolism. 2005. PMID: 15931608 Clinical Trial.
[Diagnosis of metabolic syndrome. Adaptation of diagnostic criteria in our setting. Recommendations of the HDL forum].
Ascaso JF, González-Santos P, Hernández Mijares A, Mangas Rojas A, Masana Marín L, Millán Núñez-Cortés J, Pallardo LF, Pedro-Botet J, Pérez-Jiménez F, Pintó X, Plaza I, Rubiés-Prat J, Zúñiga M; FORO-HDL. Ascaso JF, et al. Among authors: pinto x. Rev Clin Esp. 2006 Dec;206(11):576-82. doi: 10.1157/13096308. Rev Clin Esp. 2006. PMID: 17178079 Spanish. No abstract available.
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M. Ascaso J, et al. Among authors: pinto x. Am J Cardiovasc Drugs. 2007;7(1):39-58. doi: 10.2165/00129784-200707010-00004. Am J Cardiovasc Drugs. 2007. PMID: 17355165 Review.
438 results